IMMP
IMMP clinical trials: IMMUTEP Ltd
Every trial on ClinicalTrials.gov where IMMUTEP Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 16
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMMP on the catalyst calendar · IMMP registry changes
- Primary completion Aug 27, 2026ActualPhase 1NCT06637865A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy VolunteersImmutep S.A.S. · HealthyCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026ActualPhase 2/Phase 3NCT05747794Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel ChemotherapyImmutep S.A.S. · Breast CarcinomaTerminatedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2022ActualPhase 2NCT03625323Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated...Immutep S.A.S. · NSCLCCompletedIMMPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT06726265Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and...Immutep S.A.S. · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingIMMPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2024ActualPhase 2NCT04811027Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCImmutep S.A.S. · HNSCCCompletedIMMPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2025Sponsor estimatePhase 1NCT04252768A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as...Immutep S.A.S. · Metastatic Breast CancerWithdrawnIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2020ActualPhase 2NCT02614833IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast CarcinomaImmutep S.A.S. · Adenocarcinoma Breast Stage IVCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2019ActualPhase 1NCT02676869Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaImmutep Australia Pty. Ltd. · Stage IV MelanomaCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 2NCT01617629Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 StudyPrima BioMed Ltd · Epithelial Ovarian CancerCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 2NCT01068509Ovarian Cancer Vaccine for Patients in RemissionPrima BioMed Ltd · Epithelial Ovarian CancerCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT01521143Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or...Prima BioMed Ltd · Epithelial Ovarian CancerTerminatedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT02310971Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the PancreasPrima BioMed Ltd · Pancreatic Carcinoma Stage IWithdrawnIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2008ActualPhase 1NCT00351949IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)Immutep S.A.S. · Stage IV Renal Cell CarcinomaCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2009ActualPhase 1NCT00349934IMP321 Plus First-line Paclitaxel in Metastatic Breast CarcinomaImmutep S.A.S. · Metastatic Breast CancerCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2005ActualPhase 1NCT00354263Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu AntigenImmutep S.A.S. · HealthyCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2005ActualPhase 1NCT00354861A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321Immutep S.A.S. · HealthyCompletedIMMPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07102940Efti in Patients With Hormone Receptor Positive/HER2-neg Breast CancerGeorge Washington University · Breast CancerNot yet recruitingIMMPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026Sponsor estimatePhase 1NCT03252938Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid TumorsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Solid TumorsActive, not recruitingIMMPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2025ActualPhase 2NCT06128863Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma...Maria Sklodowska-Curie National Research Institute of Oncology · NeoadjuvantActive, not recruitingIMMPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 1/Phase 2NCT01308294Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma PatientsCentre Hospitalier Universitaire Vaudois · MelanomaTerminatedIMMPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2013ActualPhase 1/Phase 2NCT00365937Immunization of Disease-Free Melanoma Patients With Different HLA-A2 PeptidesCliniques universitaires Saint-Luc- Université Catholique de Louvain · MelanomaTerminatedIMMPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner